Home / Health / New Hope for Breast Cancer Patients on Endocrine Therapy
New Hope for Breast Cancer Patients on Endocrine Therapy
26 Oct
Summary
- Hybrid care pathway combines app and nurse support for patients.
- HOPE study improved patients' confidence in managing symptoms.
- Pathway showed high adoption and patient satisfaction rates.
A groundbreaking clinical trial, the HOPE study, has evaluated a hybrid care pathway designed to support women with breast cancer undergoing endocrine therapy. This innovative approach integrates a mobile application for symptom monitoring and self-management programs with personalized nurse support.
The trial results, presented on October 26, 2026, indicated that patients using the HOPE pathway reported significantly greater confidence in managing treatment-related side effects. While the average reduction in symptom burden did not achieve statistical significance, exploratory analyses suggested a notable benefit for actively engaged patients.
Further findings revealed high patient adoption and satisfaction, with 90% of participants finding the pathway useful and recommending it. The study enrolled a diverse group of women, reflecting a broad patient population in terms of age and background.
Additional analyses are underway to assess the long-term impact on symptom burden, adherence, and physical activity. Plans for a HOPE 2 study are in development to offer more personalized and extended support, particularly for younger patients.
